Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1996 1
2006 1
2007 1
2010 1
2012 2
2013 3
2014 2
2015 1
2017 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
CAPRIE Steering Committee. CAPRIE Steering Committee. Lancet. 1996 Nov 16;348(9038):1329-39. doi: 10.1016/s0140-6736(96)09457-3. Lancet. 1996. PMID: 8918275 Clinical Trial.
BACKGROUND: Many clinical trials have evaluated the benefit of long-term use of antiplatelet drugs in reducing the risk of clinical thrombotic events. ...There were ten (0.10%) patients in the clopidogrel group with significant reductions in neutrophils (< 1.2 x 10(9)/L …
BACKGROUND: Many clinical trials have evaluated the benefit of long-term use of antiplatelet drugs in reducing the risk of clinical t …
Investigation of the enhanced antitumour potency of STING agonist after conjugation to polymer nanoparticles.
Dosta P, Cryer AM, Dion MZ, Shiraishi T, Langston SP, Lok D, Wang J, Harrison S, Hatten T, Ganno ML, Appleman VA, Taboada GM, Puigmal N, Ferber S, Kalash S, Prado M, Rodríguez AL, Kamoun WS, Abu-Yousif AO, Artzi N. Dosta P, et al. Among authors: lok d. Nat Nanotechnol. 2023 Nov;18(11):1351-1363. doi: 10.1038/s41565-023-01447-7. Epub 2023 Jul 13. Nat Nanotechnol. 2023. PMID: 37443252
This is shown to increase stability and loading, thereby expanding the therapeutic window in multiple syngeneic tumour models, enabling the study of how the long-term fate of the nanoparticles affects the immune response. In a melanoma mouse model, primary tumour clearance …
This is shown to increase stability and loading, thereby expanding the therapeutic window in multiple syngeneic tumour models, enabling the …
Two-year outcome after early or late Intervention in non-ST elevation acute coronary syndrome.
Badings EA, Remkes WS, The SH, Dambrink JE, Tjeerdsma G, Rasoul S, Timmer JR, van der Wielen ML, Lok DJ, Hermanides RS, Van Wijngaarden J, Suryapranata H, van 't Hof AW. Badings EA, et al. Among authors: lok dj. Open Heart. 2017 Mar 2;4(1):e000538. doi: 10.1136/openhrt-2016-000538. eCollection 2017. Open Heart. 2017. PMID: 28409008 Free PMC article.
OBJECTIVE: To compare long-term outcome of an early to a delayed invasive strategy in high-risk patients with non-ST elevation acute coronary syndrome (NSTE-ACS). ...Patients were randomised to either an early (angiography and revascularisation if appropriate <12 hours) …
OBJECTIVE: To compare long-term outcome of an early to a delayed invasive strategy in high-risk patients with non-ST elevation acute …
Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure.
Lok DJ, Lok SI, Bruggink-André de la Porte PW, Badings E, Lipsic E, van Wijngaarden J, de Boer RA, van Veldhuisen DJ, van der Meer P. Lok DJ, et al. Clin Res Cardiol. 2013 Feb;102(2):103-10. doi: 10.1007/s00392-012-0500-y. Epub 2012 Aug 12. Clin Res Cardiol. 2013. PMID: 22886030
BACKGROUND: Galectin-3 (Gal-3) is a recently discovered marker for myocardial fibrosis and elevated levels are associated with an impaired outcome after short-term follow-up in heart failure (HF) patients. However, whether Gal-3 is related to cardiac remodeling and outcome …
BACKGROUND: Galectin-3 (Gal-3) is a recently discovered marker for myocardial fibrosis and elevated levels are associated with an impaired o …
Early Invasive Versus Selective Strategy for Non-ST-Segment Elevation Acute Coronary Syndrome: The ICTUS Trial.
Hoedemaker NPG, Damman P, Woudstra P, Hirsch A, Windhausen F, Tijssen JGP, de Winter RJ; ICTUS Investigators. Hoedemaker NPG, et al. J Am Coll Cardiol. 2017 Apr 18;69(15):1883-1893. doi: 10.1016/j.jacc.2017.02.023. J Am Coll Cardiol. 2017. PMID: 28408018 Free article. Clinical Trial.
BACKGROUND: The ICTUS (Invasive Versus Conservative Treatment in Unstable Coronary Syndromes) trial compared early invasive strategy with a selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) and an elevated cardiac troponin T. …
BACKGROUND: The ICTUS (Invasive Versus Conservative Treatment in Unstable Coronary Syndromes) trial compared early invasive strategy with a …
Long-term follow-up in optimally treated and stable heart failure patients: primary care vs. heart failure clinic. Results of the COACH-2 study.
Luttik ML, Jaarsma T, van Geel PP, Brons M, Hillege HL, Hoes AW, de Jong R, Linssen G, Lok DJ, Berge M, van Veldhuisen DJ. Luttik ML, et al. Among authors: lok dj. Eur J Heart Fail. 2014 Nov;16(11):1241-8. doi: 10.1002/ejhf.173. Epub 2014 Oct 10. Eur J Heart Fail. 2014. PMID: 25302753 Free article. Clinical Trial.
However, little is known about adherence to HF guidelines and adherence to the medication regimen in these home-based programmes. The aim of the current study was to determine whether long-term follow-up and treatment in primary care is equally effective as follow-up at a …
However, little is known about adherence to HF guidelines and adherence to the medication regimen in these home-based programmes. The aim of …
EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot).
Maggioni AP, Dahlström U, Filippatos G, Chioncel O, Leiro MC, Drozdz J, Fruhwald F, Gullestad L, Logeart D, Metra M, Parissis J, Persson H, Ponikowski P, Rauchhaus M, Voors A, Nielsen OW, Zannad F, Tavazzi L; Heart Failure Association of ESC (HFA). Maggioni AP, et al. Eur J Heart Fail. 2010 Oct;12(10):1076-84. doi: 10.1093/eurjhf/hfq154. Epub 2010 Aug 29. Eur J Heart Fail. 2010. PMID: 20805094 Free article.
Moreover, this study offered the opportunity to refine the organizational structure of a long-term, extended European network....
Moreover, this study offered the opportunity to refine the organizational structure of a long-term, extended European network....
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo.
Bentley-Lewis R, Aguilar D, Riddle MC, Claggett B, Diaz R, Dickstein K, Gerstein HC, Johnston P, Køber LV, Lawson F, Lewis EF, Maggioni AP, McMurray JJ, Ping L, Probstfield JL, Solomon SD, Tardif JC, Wu Y, Pfeffer MA; ELIXA Investigators. Bentley-Lewis R, et al. Am Heart J. 2015 May;169(5):631-638.e7. doi: 10.1016/j.ahj.2015.02.002. Epub 2015 Feb 12. Am Heart J. 2015. PMID: 25965710 Free article. Clinical Trial.
Incremental prognostic power of novel biomarkers (growth-differentiation factor-15, high-sensitivity C-reactive protein, galectin-3, and high-sensitivity troponin-T) in patients with advanced chronic heart failure.
Lok DJ, Klip IT, Lok SI, Bruggink-André de la Porte PW, Badings E, van Wijngaarden J, Voors AA, de Boer RA, van Veldhuisen DJ, van der Meer P. Lok DJ, et al. Am J Cardiol. 2013 Sep 15;112(6):831-7. doi: 10.1016/j.amjcard.2013.05.013. Epub 2013 Jun 29. Am J Cardiol. 2013. PMID: 23820571
Concentrations of circulating NT-proBNP, growth differentiation factor 15 (GDF-15), high-sensitivity C-reactive protein (hs-CRP), galectin-3 (Gal-3), and high-sensitivity troponin T (hs-TnT) were measured and related to all-cause long-term mortality. Of 209 patients (age 7 …
Concentrations of circulating NT-proBNP, growth differentiation factor 15 (GDF-15), high-sensitivity C-reactive protein (hs-CRP), galectin-3 …
Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT).
van Veldhuisen DJ, Man in 't Veld AJ, Dunselman PH, Lok DJ, Dohmen HJ, Poortermans JC, Withagen AJ, Pasteuning WH, Brouwer J, Lie KI. van Veldhuisen DJ, et al. Among authors: lok dj. J Am Coll Cardiol. 1993 Nov 15;22(6):1564-73. doi: 10.1016/0735-1097(93)90579-p. J Am Coll Cardiol. 1993. PMID: 7901256 Free article. Clinical Trial.
OBJECTIVES: This study was conducted to determine the efficacy and safety of long-term treatment with the orally active dopamine agonist ibopamine in patients with mild to moderate chronic congestive heart failure and to compare the results with those of treatment with dig …
OBJECTIVES: This study was conducted to determine the efficacy and safety of long-term treatment with the orally active dopamine agon …
15 results